HSAN-9

TECPR2 | 2021

What Is HSAN-9?

HSAN-9 is a type of CMT caused by autosomal recessive mutations in the TECPR2 gene. This gene provides instructions for making a protein involved in autophagy, the process by which nerve cells clear and recycle their internal components. Mutations in the TECPR2 gene disrupt this function, leading to impaired nerve signal transmission.

HSAN-9 is autosomal recessive, meaning that both copies of the gene must have a mutation to cause this subtype.

Clinical Features

The age of symptom onset in HSAN-9 is variable, ranging from childhood to adulthood. The disease involves loss of sensation that begins in the hands and feet (glove-and-stocking distribution) and progresses over time towards the center of the body. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

HSAN-9 symptoms may include:

  • Progressive loss of sensation in the feet and hands
  • Loss of pain and temperature sensation
  • Autonomic dysfunction
  • Cognitive impairment and developmental delay
  • Spasticity (muscle stiffness) and ataxia (impaired balance and coordination)
  • Reduced or absent reflexes
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Distal weakness that develops as the disease progresses
  • Foot drop
  • Additional symptoms not listed here

Disease Course

HSAN-9 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
HSAN-9

Classification
HSAN

Neuropathy Type
Axonal

Inheritance Pattern
autosomal recessive

Genetic Context

HGNC-Approved Gene Symbol
TECPR2

Gene Full Name
Tectonin Beta-Propeller Repeat Containing 2

HGNC Gene Alias(es)
KIAA0329

Chromosome
14q32.31

Zygosity of Responsible Variant
Homozygous or Compound Heterozygous

Variant Mechanism

Loss of Function (LoF)

Details

Mechanistic basis:
Biallelic

Confidence:
High

Prediction:
The literature predicts a biallelic loss-of-function mechanism for HSAN-9: recessive TECPR2 variants are predominantly truncating or otherwise deleterious changes that abolish TECPR2, required for autophagosome formation and ER-Golgi trafficking, so both copies must be lost. Because a wild-type copy is protective, restored wild-type is predicted to rescue, consistent with loss rather than a dominant-negative or gain-of-function effect.

Rationale:
Recessive truncating or deleterious TECPR2 variants abolish this autophagy and trafficking protein, and a single wild-type copy suffices, so restored wild-type is predicted to rescue: a biallelic loss of function, with no dominant-negative or gain-of-function signal.

ClinVar Pathogenic Variants

View HSAN-9 ClinVar Variants

HSAN-9 OMIM Entry

HSAN-9 OMIM

TECPR2 OMIM Entry

TECPR2 OMIM

More Info

HSAN-9 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Clinical, Neuroimaging, and Molecular Spectrum of TECPR2-Associated Hereditary Sensory and Autonomic Neuropathy with Intellectual Disability

Authors

Neuser, S., Brechmann, B., Heimer, G., Brösse, I., Schubert, S., O’Grady, L., Zech, M., Srivastava, S., Sweetser, D. A., Dincer, Y., Mall, V., Winkelmann, J., Behrends, C., Darras, B. T., Graham, R. J., Jayakar, P., Byrne, B., Bar-Aluma, B. E., Haberman, Y., Szeinberg, A., Aldhalaan, H.M., Hashem, M., Tenaiji, A.A., Ismayl, O., Al Nuaimi, A.E., Maher, K., Ibrahim, S., Khan, F., Houlden, H., Ramakumaran, V.S., Pagnamenta, A.T., Posey, J.E., Lupski, J.R., Tan, W., ElGhazali, G., Herman, I., Muñoz, T., Repetto, G.M., Seitz, A., Krumbiegel, M., Poli, M.C., Kini, U., Efthymiou, S., Meiler, J., Maroofian, R., Alkuraya, F.S., Jamra, R.A., Popp, B., Ben-Zeev, B., Ebrahimi-Fakhari, D.

Publication Date
April 13, 2021

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Jean-Martin Charcot lecturing at the Salpêtrière while comparing anatomical illustrations of a cavovarus Charcot-Marie-Tooth (CMT) foot and a Charcot neuroarthropathy foot, highlighting two different conditions that share the Charcot name.


A Name That Does Too Much Work

Jean-Martin Charcot's name appears throughout medicine, but nowhere does it create more confusion than in the foot. Learn why the CMT foot and Charcot neuroarthropathy, also known as Charcot foot, share a name yet differ in how they develop, appear, and are managed.


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.